Acinetobacter baumannii clinical infection trends and susceptibility testing.docVIP

 PAGE \* MERGEFORMAT 9 Acinetobacter baumannii clinical infection trends and susceptibility testing [Abstract] described the purpose of clinical Acinetobacter baumannii infection trends and drug resistance, rational use of drugs to help clinicians. Methods for inspection routine bacterial culture of clinical specimens to identify ATB microbial analyzer, select the KB paper diffusion method for susceptibility testing, using WHONET 5.4 and SPSS 14.0 software Acinetobacter baumannii isolated for statistical analysis. Results of Acinetobacter baumannii isolation rate of 12.74%, the most common respiratory tract specimens (88.4%, neurological surgery and ICU ward with severe isolated Acinetobacter baumannii accounted for 41.5%, 24.4%, Acinetobacter baumannii to imipenem, meropenem, cefoperazone / sulbactam resistance rates were: 8.5 %, 18.4%, 28.2% to piperacillin, levofloxacin, ceftazidime, amikacin, cefepime resistance rate above 80%, respectively: 87.5%, 85.5%, 82.4%, 81.8% 81.6%. In addition, the detected three (1.83% Pan-resistant (PDR A. baumannii. Conclusion separation rate of Acinetobacter baumannii is an important condition for the current hospital infection pathogens, their resistance is serious, should be lead to clinical attention. [Keywords:] Acinetobacter baumannii, nosocomial infection, drug resistance Acinetobacter baumannii is one of the main pathogens of clinical common, as opportunistic pathogens of infection more common in patients after surgery, radiotherapy or chemotherapy of cancer patients and long-term hospitalized patients with chronic diseases, these groups of immunocompromised and prone to nosocomial infection . Acinetobacter baumannii often cause respiratory infections, bacteremia, meningitis, otitis media, urinary tract and wound infections, is a serious pathogen of nosocomial infection [1 3]. In recent years, the abuse of broad-spectrum antibiotics, which the growing phenomenon of bacterial resistance, multiple drug-resistant